Company Overview and News

Spookfish signs licence agreement with Western Australian Land Information Authority

Spookfish Ltd (ASX:SFI) has signed a licence agreement with the Western Australian Land Information Authority (Landgate).
Upvote Downvote

Spookfish aerial camera system approval allows large-scale manufacture

Spookfish Ltd (ASX:SFI) has received Civil Aviation Safety Authority (CASA) approval for the final stage of a Supplemental Type Certificate (STC) program for its aerial camera system.
Upvote Downvote

Spookfish wins contract to provide aerial imagery to CIMIC Group

Spookfish Limited (ASX:SFI) has been awarded a contract to provide CIMIC Group (ASX:CIM) with aerial imagery across Australia, after a competitive tender process.
Upvote Downvote

Spookfish secures Chinese partner to market its aerial imagery technology

Spookfish Ltd (ASX:SFI) has entered into an evaluation agreement with Global Earth Ventures Limited to explore the market for its aerial imagery and data analytics in China.
Upvote Downvote

Spookfish crosses major milestone following U.S. flight test program

Spookfish (ASX:SFI) achieved a significant commercial milestone by gaining acceptance following an extensive U.S. flight test program by EagleView Technologies Inc.
Upvote Downvote

Spookfish gets ready to raise

Spookfish (ASX:SFI) has been granted a trading halt by the ASX, pending details of a capital raising.
Upvote Downvote

Spookfish progressing geospatial technologies with North American partner

Spookfish is developing an integrated suite of technologies, enabling the capture, processing, archiving and delivery of geospatial imagery and data over vast areas.
Upvote Downvote

Trading Halt

Upvote Downvote

Quarterly Report

Upvote Downvote


Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN:, Inc Analysis and Research Report

2018-04-25 - Asif

Overview opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...